GLORIA is an international investigator – initiated trial aiming to prove (or disprove) that the addition of chronic low dose glucocorticoids to current anti-rheumatic therapy is cost-effective and safe, in elderly patients with Rheumatoid Arthritis (RA). About 50% of patients are currently treated with this strategy.
GLORIA is funded by the EU Horizon 2020 Program. >>
The next EULAR Annual European Congress of Rheumatology will take place from 14 - 17 June 2017 in Madrid, Spain.
The annual EULAR Congress continues to be a major event for the exchange of scientific and clinical information. It will be a platform to facilitate interactions between patients, medical doctors, scientists, health professionals, and professionals representing the pharmaceutical ind Read more
Feb 2, 2017 - Recent Publications \ News from GLORIA
To describe the perception on the current role of systemic glucocorticoids (GC) in the management of rheumatoid arthritis (RA) by examining their importance and the current level of evidence in recent guidelines, and to identify open questions to be addressed in future guidelines and research projects.
Systematic literature review using the databases PubMed, EMBASE and Read more
We are pleased to announce that we have submitted an EU-Horizon 2020 proposal for a new trial and project to complement GLORIA.
In Call PM10, the EU requested proposals for studies "evaluating existing health care in the adult population”. The call text was almost identical to the call text on the elderly in which GLORIA was successful.
As more than half of the RA population is no Read more
It is with great pleasure that we announce that the first patient has now been included in GLORIA trial. The patient was included in VU University Medical Center, Amsterdam, Netherlands. GLORIA trial finally has lift off!